Navigation Links
Lpath CEO, Scott Pancoast, to Present Live Online at on June 2 at 1 PM EDT

NEW YORK, May 26, 2011 /PRNewswire/ -- Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, will present on on June 2, 2011 at 1:00 PM EDT.

Lpath's president and CEO, Scott Pancoast, will discuss the company's progress, including status updates on the PEDigree and Nexus clinical trials, where the company's ocular drug candidate, iSONEP™, is being investigated in human proof-of-concept studies.

To access, follow this link: and then click on: "Register/Watch Event Now!" Attendees are advised to pre-register and receive event updates.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time in the virtual "presentation hall." After the presentation investors are invited to ask questions and download shareholder materials from the company's "virtual booth." A replay of the event will be available for 90 days.

Lpath entered into an agreement with Pfizer in late 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP for ocular indications. Pfizer and Lpath are collaborating closely on the two iSONEP clinical trials.

Pfizer also has a right of first refusal, which expires in late 2013, for Lpath's cancer drug candidate, ASONEP™. Lpath is planning to further investigate ASONEP in a Phase 2 trial involving renal cell carcinoma patients and perhaps in a second trial involving patients with prostate cancer or neuroblastoma.

About Lpath

San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- iSONEP for wet AMD and ASONEP for cancer -- have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit

About, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Forward-Looking Statements

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the eventual commercial viability of the Company's drug programs; the eventual revenues that the Company would attain if the drug eventually gets approved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the results of any future clinical trials for iSONEP may not be favorable and the Company may never receive regulatory approval for iSONEP; and the Company may not be able to secure the funds necessary to support its clinical trial and product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Lpath, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Technest Holdings, Inc. to Acquire AccelPath, LLC; Issue Contingent Value Rights to Common Stockholders; and Issue Shares of Its Series E 5% Convertible Preferred Stock
4. Lpath, Inc. CEO to Present Live, Online at on May 5th
5. Lpath, Inc. CEO Presentation Now Available for On-demand Viewing at
6. DNA Testing Reveals Roots Authors Scottish Ancestry
7. Scottsdale Facility to Be First in U.S. to Showcase True REST Technology
8. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
9. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
10. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
11. Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain
Post Your Comments:
(Date:11/30/2015)... MOUNTAIN VIEW, Calif. , Nov. 30, ... has been the norm in U.S. medical ... obsolete. The increasingly popular accountable care payer-provider ... payment models and, in their wake, alter ... or quality-based payments will push forward new ...
(Date:11/30/2015)... 2015 Cumberland Pharmaceuticals (CPIX), today announced that A.J. ... on December 3, 2015. TIME: 3:15p.m. ET LINK: ... LINK: --> DATE: Thursday, ... --> --> This ... invited to ask the company questions in real-time - both ...
(Date:11/30/2015)... Varian Medical Systems (NYSE: VAR ) has signed ... Apollo Hospitals Group, the largest hospital chain in India ... technologists in the country. The MoU was signed by Dr. ... Ashok Kakkar , Varian,s India managing director, ... , Varian intends to deploy its Access to Care program ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... The directory is specialized and only includes chiropractic clinics in the US. , ... and trustworthy alternative health practitioner when back pain sets in. When people are ...
(Date:11/30/2015)... ... ... On Saturday, October 24th, 2015, at the Mill Race Park in Downtown ... walk known as “Making Strides Against Breast Cancer”. Patients and staff members from A ... Battle Creek, joined in for this campaign that sought to raise donations that will ...
(Date:11/30/2015)... ... 30, 2015 , ... Rick Sommer, president of Intellitec Solutions, ... of Information Systems course. Based in Wilmington Delaware, Intellitec Solutions is an established ... student in the Enterprise Resource Planning (ERP) Systems class. The course focuses on ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of ... Public Television’s Travel With Kids to promote family vacations around the world. ... they explore international destinations and educate families about the people and places of the ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... ... top choice for innovative, patient centered orthopedic care. Led by John Vitolo, ... your injury or chronic condition, the team at Advocare Orthopedic & Sports Medicine ...
Breaking Medicine News(10 mins):